Take part in a clinical trial
Community screening and management of Hepatitis C, B and delta in the Mongolian population living in France
Study coordinated by Dr François Bailly Hôpital de la Croix Rousse, Lyon
Mondelta Study
Viral hepatitis viruses can, in some cases, lead to the development of a serious liver disease called cirrhosis or to liver cancer, both of which may become complicated and result in the patient’s death. Hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis Delta virus (HDV) are the main viruses responsible for these complications.
In Mongolia, liver cancer–related mortality is among the highest in the world, due to the high prevalence of these viral infections, particularly HBV and HDV. These infections are asymptomatic, and patients experience no pain or complaints associated with viral hepatitis; therefore, systematic screening is essential for diagnosis.
There are simple and rapid tools to screen for these conditions (such as rapid diagnostic orientation tests, or RDTs), which allow referral to specialized care pathways. The RDT is performed using a drop of blood taken from the fingertip and provides a result within a few minutes. In the case of a positive RDT, a confirmatory blood test is required. Once viral infection is diagnosed, specific treatments are available that reduce liver complications and virus transmission.
The Mondelta study
Primary objective
The objective of this study is to screen for viral hepatitis B, C and D in the Mongolian population living in France by Rapid Diagnostic Orientation Test (RDOT) on the occasion of dedicated days.
This study is intended for the Mongolian population, over 15 years old, living in France. For underage participants, a parent or legal guardian must be present.
Strategy
Screening days will be offered in several centers across France, with information sessions about these liver diseases. A Mongolian-speaking person will be present to answer participants’ questions and help ensure the smooth running of the day.
Two rapid diagnostic orientation tests (RDTs) will be performed to screen for hepatitis B virus and hepatitis C virus, along with a self-administered questionnaire to collect information about medical history, treatments, sociodemographic data, and lifestyle habits.
If one or both RDTs are positive, a member of the medical team, accompanied by a translator if needed, will explain the results. Diagnostic confirmation will then be carried out using a blood test, either on the same day or later, depending on your center’s organization.
If the diagnosis is confirmed, the participant will be referred to a hepatology consultation for specialized care.
Cities participating in the study:
Lyon, Clermont-Ferrand, Annecy, Tours, Bordeaux, Grenoble, Rennes, Paris and its suburbs, Lille, Rouen, Strasbourg.
If you have any questions, you can contact us by email: mondelta-U1350@inserm.fr
At a later stage, information on the dates and locations of the screening days will be communicated on this website.
Would you like to take part in a clinical trial?
Or get more information?
Contact us and we’ll guide you toward the department that can best inform you about the clinical trials underway, depending on the disease in question, the patient’s profile and their situation.
Our teams will then be able to provide you the best possible treatment.
Send us an email to
contact@ihu-hepatolyon.fr
